We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Backs Merck’s Bezlotoxumab for Clostridium Difficile Infection
FDA Advisory Committee Backs Merck’s Bezlotoxumab for Clostridium Difficile Infection
An FDA advisory committee recommended the approval of Merck’s bezlotoxumab to prevent Clostridium difficile infection recurrence in patients 18 and older.